The financing was supported by new investors including InnoSpark alongside returning backers such as the Development Bank of Wales.
"This is the most comprehensive validation of our platform thus far. While identifying antibodies to GPCRs has traditionally been a complex and time-intensive process requiring expensive specialist technology and training, we have demonstrated that Antiverse’s drug discovery platform can achieve this in a fraction of the time and cost. GPCRs are commercially interesting targets associated with various indications, and these antibodies offer a path to first in vivo results and can potentially be our first assets. I would like to thank our investors, this funding will enable us to continue to develop these assets in-house with our academic collaborators."
Octopus Ventures led the Series B round to support expansion into new vehicle segments and international markets.
"At Flock, we believe that insurers should help customers save time, money, and even lives. With our radically different insurance model, enabled by an immense amount of data, we hope to actively reduce the number of people needlessly killed or injured on the road."
The seed round was led by Y Combinator alongside Garage Capital and FoundersX Ventures.
"Businesses are continually up against it to find cost efficiencies, while creating more hybrid working environments for their people. Mobile devices, whether used for calls, messages or video meetings, are an essential tool for doing business. Devyce makes it easier and cheaper for companies to help their people make best use of the devices they already have at their disposal, wherever they are located."
.png)
